APG-115 in Patients With Advanced Solid Tumors or Lymphomas
Completed
Ascentage Pharma Group Inc.
Phase 1
APG-115 is a novel, orally active small-molecule mouse double minute 2 homolog (MDM2)
inhibitor. Mechanistically, APG-115 increases p53 and p21 overexpression, activates p53 -
mediated apoptosis in tumor cells retaining wild-type p53. APG-115 has shown strong dose- and
schedule-dependent antitumor activities in multiple human cancer xenograft and a patient
derived xenograft (PDX) models. The preclinical data generated from APG-115 suggest that it
may have a broad therapeutic potential for the treatment of human cancer as a single agent
and in combination with other classes of anticancer drugs. APG-115 is intended for the
treatment of patients with advanced solid tumors and lymphomas. Upon completion of the Phase
1 dose escalation study to establish the maximum tolerated dose (MTD), dose-limiting
toxicities (DLTs), and/or recommended phase 2 dose (RP2D), several phase Ib/II studies will
be implemented accordingly.
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Recruiting
Merck Sharp & Dohme Corp.
Phase 1/Phase 2
Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab.
Part 2 is phase II design of APG-115 at recommended phase 2 dose (RP2D) in combination with
pembrolizumab in patients with programmed cell death protein 1 (PD-1)/programmed death-ligand
1 (PD-L1) refractory/relapsed melanoma or NSCLC, lung adenocarcinoma with STK11 mutation,
solid tumors with P53 WT and ATM mutation, P53 WT and MDM2 amplification liposarcomas,
PD-1/PD-L1 refractory/relapsed urothelial carcinoma without FGFR translocation mutation, and
MPNST.
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Recruiting
Ascentage Pharma Group Inc.
Phase 1/Phase 2
Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab.
Part 2 is phase II design of APG-115 at recommended phase 2 dose (RP2D) in combination with
pembrolizumab in patients with programmed cell death protein 1 (PD-1)/programmed death-ligand
1 (PD-L1) refractory/relapsed melanoma or NSCLC, lung adenocarcinoma with STK11 mutation,
solid tumors with P53 WT and ATM mutation, P53 WT and MDM2 amplification liposarcomas,
PD-1/PD-L1 refractory/relapsed urothelial carcinoma without FGFR translocation mutation, and
MPNST.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
